share_log

和黃醫藥:自願性公告 - 和黃醫藥與阿斯利康宣佈SAVANNAH II期研究中泰瑞沙(TAGRISSO)和賽沃替尼(savolitinib)聯合療法治療高MET過表達和/或擴增水平的肺癌患者客觀緩解率(ORR)達49%

HUTCHMED: VOLUNTARY ANNOUNCEMENT- HUTCHMED and AstraZeneca Announce that TAGRISSO Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

Aug 8, 2022 04:30
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more